Shattuck Labs, Inc.
STTKShattuck Labs is a clinical-stage biotechnology company focused on developing first-in-class monoclonal and bispecific antibodies for inflammatory and immune-mediated diseases.
Earnings
Next report
Nov 10, 2026 (in 2 months)Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
By net margin
Profile
Shattuck Labs is a clinical-stage biotechnology company focused on developing first-in-class monoclonal and bispecific antibodies for inflammatory and immune-mediated diseases. The company leverages protein engineering expertise to target the Death Receptor 3 (DR3) pathway, aiming to provide more complete blockade and superior immunogenicity profiles compared to existing ligand-blocking therapies. Their core value proposition lies in addressing the limitations of current treatments for conditions like Crohn's disease and ulcerative colitis.
A clinical-stage pioneer in DR3-targeting antibodies, positioning itself as a potentially best-in-class alternative to established TL1A-blocking therapies.
FAQ
- What is Shattuck Labs, Inc.'s market cap?
- Shattuck Labs, Inc. (STTK) has a market capitalization of $590.1M and trades on NASDAQ.
- What is Shattuck Labs, Inc.'s revenue and profitability?
- Shattuck Labs, Inc. generated $1.0M in trailing twelve-month revenue with a net loss of $52.6M, representing a net margin of -5256.8%, with free cash flow of -$41.2M. The latest reported period is Q2 2026.
- Who are Shattuck Labs, Inc.'s competitors?
- Shattuck Labs, Inc.'s key competitors include AbbVie, Eli Lilly and Company, Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- Where is Shattuck Labs, Inc. headquartered?
- Shattuck Labs, Inc. is headquartered in United States of America and employs approximately 75 people. It has been publicly traded since 2020.
